anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an agent capable of releasing a drug in a state of fine particles, by uniformly mixing a hardly soluble drug, polymers swellable with water, and polymers soluble in an organic solvent as well as in a buffer solution and/or water-soluble univalent metal salt of polymers. CONSTITUTION:The objective slowly releasing preparation can be produced by uniformly mixing (A) 100 pts. of a hardly soluble drug having an average particle diameter of <=10mum and a water-solubility of <=0.1%, (B) >=25 pts. of polymers swellable with water (e.g., hydroxypropyl cellulose having low substitution degree) and (C) polymers soluble in an organic solvent and soluble in a buffer solution of pH1-9 (e.g., hydroxypropyl cellulose) and/or (D) >=0.5 pts. of water-soluble univalent metal salt of polymers (e.g., carboxymethyl cellulose sodium salt). The agent slowly releases the component A in the form of fine particles. The releasing period can be varied by changing the compounding ratio of the component B to the component C and/or component D.
In the preparation room, the parturient will relax in supine position with left uterine displacement by placing a wedge below the right hip. Appropriate size non-invasive blood pressure (NIBP) cuff for the arm and ankle will be chosen according to arm circumference just proximal to antecubital fossa and ankle circumference just above the malleoli, respectively. The cuff's bladder will be directed anteriorly in the arm and in posteriorly in the leg. Simultaneous NIBP measurement of both arms then both ankles will be done. The arm and the ankle with the higher reading will be used for intraoperative NIBP assessment. The baseline reading of the arm and ankle will be obtained as average of 3 reading 2 minutes apart. Simultaneous arm and ankle NIBP measurement will be every 2 minutes from injection of local anesthetic into subarachnoid space till 5 minutes after delivery, then every 5 minutes till the end of surgery. Left uterine displacement will be continued intraoperatively till the delivery. All NIBP measurements will be collected by a research assistant who have no role in parturient management.

Position of the parturient during the spinal anesthesia, drug dosage, fluid management and vasopressor administration will be according to local protocols and the discretion of the attending anesthetist. Intraoperative blood pressure management will be according to the arm NIBP readings
Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the SCD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Participants assigned to the SCD received a three3-day starter diet as recommended in Breaking the Vicious Cycle. Meals were designed to be heated in an oven or microwave. No other preparation was required.
Increasing prevalence of overweight and obese worldwide, non-alcoholic fatty liver disease (NAFLD) is commonly diagnosed in daily clinical practice. Weight reduction has been the only strategy established thus far to reduce hepatic lipid levels. Thus, dietary restriction and exercise focusing on weight reduction is recommended as the cornerstone for managing NAFLD. Recent reports have indicated that increased exercise greatly reduces hepatic fat accumulation and inflammation and the related oxidative stress levels outweigh those achieved by dietary restriction alone. Clear guidelines for such a "lifestyle physical activity" for NAFLD management are currently lacking. The type of physical activity such as, aerobic or resistant exercise required to reduce liver fat content remains unclear.The purpose of this study is to determine whether aerobic exercise should provide improvement of hepatic fat content and inflammation as well as metabolic profiles and anthropometric parameters better than resistant exercise.
FIELD: medicine, biochemistry. SUBSTANCE: pharmaceutical composition has pharmaceutically acceptable carrier and an active component - effective amount of a mixture of L-glutamic acid, glycine and sulfur-containing amino acid taken from the group including cysteine, cystine and methionine at mass ratio of components = 1:1:1. Pharmaceutical composition can be prepared in the form of powder, tablet or solution. It has each of the indicated components at amount 0.1-0.2 g per a single dose. Pharmaceutically acceptable carrier consists of water or methylcellulose. Composition is used for prophylaxis and treatment of chronic alcoholism, intoxication with aromatic hydrocarbons and for resistance increase to hypoxia and protection from radiation damage by sublingual administration at effective dose. EFFECT: enhanced effectiveness of composition. 8 cl, 1 dwg , 11 tbl
FIELD: medicine; diagnostics of occupational pathologies; detection of persons affected with injuries of peripheral nervous system under stationary and ambulatory conditions. SUBSTANCE: mixture consisting of 9 parts chloroform and 1 part ethanol is applied onto back surface of patient's hand, onto volar surface of his (her) shoulder and forearm in their median third. Next latent period is measured until appearance of burning sensation at mixture application point. If extended latent period is established at least two mixture application points, namely, over 2 min. on back surface of hand, and over 1 min. in forearm or shoulder, patient is classified as belonging to category of persons affected with injuries of peripheral nervous system having vibratory genesis. EFFECT: greater sensitivity of diagnosis; reduced risk for introducing inductions to patient. 2 tbl
BACKGROUND: Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS), a relatively common cause of late-onset progressive ataxia, is a genetic disease characterised by biallelic pentanucleotide AAGGG repeat expansion in intron 2 of the replication factor complex subunit 1 gene. Herein, we describe the first molecularly confirmed CANVAS family with five affected siblings from Turkey.
CASE PRESENTATION: The family comprised seven siblings born from healthy non-consanguineous parents. CANVAS phenotype was present in five of them; two were healthy and asymptomatic. Chronic cough was the first symptom reported in all five siblings, followed by the development of sensory symptoms, oscillopsia and imbalance. Clinical head impulse test (HIT) was positive in all cases and video HIT performed on three patients revealed very low vestibulo-ocular reflex gains bilaterally. Magnetic resonance imaging and nerve conduction studies revealed cerebellar atrophy and sensory neuronopathy, respectively. RP-PCR confirmed the homozygous presence of the AAGGG repeat expansion in all five cases.
CONCLUSION: Genetic screening for CANVAS should be considered in all patients with late-onset ataxia, sensory disturbances and vestibular involvement, especially in the presence of chronic cough.
This is a Phase 0, multicenter (when more than one hospital work on a medical research study) study including participants taking aripiprazole, olanzapine, paliperidone or risperidone. Participants will provide blood samples to be used in development of antipsychotic immunoassays. At different times, assay development will require venous, capillary, or both types of blood samples. Overall, at a single study visit, a minimum of approximately 0.1 milliliter (mL) to a maximum of approximately 15 mL of blood will be collected from all sources. Across all study visits, a maximum of 450 mL of blood will be collected from a participant. The frequency of collections (study visits) will depend on the needs of assay development. A particular participant may participate for only 1 sample collection or multiple sample collections (study visits). This study will continue for an indefinite period of time. The participant's direct involvement in the study will be continued until the study is ended, the participant has given 450 mL of blood, or the participant withdraws consent or is excluded from participation for medical and/or inclusion/exclusion criteria reasons. Participants' safety will be monitored throughout the study.
The present invention relates to methods and compositions for use in mediating an immunosuppressive reaction. The compositions of the invention comprise exosomes having immunosuppressive activity. Such exosomes may be derived from a variety of different cell types, including antigen presenting cells such as dendritic cells and macrophages. Prior to isolation of exosomes, the cells may be genetically engineered to express molecules capable of enhancing the immunosuppressive activity of said exosomes and/or may be exposed to one or more agents, such as cytokines or cytokine inhibitors, which are also capable of enhancing the immunosuppressive activity of exosomes. The present invention also relates to the use of such exosomes for the treatment of diseases and disorders associated with undesirable activation of the immune system. The present invention also includes exosomes isolated directly from serum that have been shown to be immunosuppressive.
FIELD: medicine, oncology. SUBSTANCE: suggested preparation represents graphite hydrosulfate of the following formula C       +   24       HSO       -   4       H 2 SO 4  containing about 1 g sulfuric acid/g graphite at liquid density being 1.815 g/cm 3 . Moreover, the preparation is declared containing graphite hydrosulfate and a filler at volumetric ratios being 1:2 - 1:1. Method to treat patients is characterized by applying the preparation either as the liquid or an ointment upon affected cutaneous area. The innovation has a selective action upon tumor vessels by not destroying the connective tissue of adjacent cutaneous areas. EFFECT: higher penetrating capacity. 9 cl
PROBLEM TO BE SOLVED: To obtain a skin astringent for a cosmetic, having excellent stability and feeling in use, comprising a substance derived from a natural substance having high safety, by including a protein aggregating substance collected from prune flesh as an active ingredient. SOLUTION: This skin astringent comprises a protein aggregating substance collected from prune flesh as an active ingredient. Preferably the active ingredient is obtained by extracting prune flesh with water or a hydrous alcohol or treating it with a cellulase or a hemicellulase or a pectinase. In the case of the former, the hydrous alcohol is preferably a lower aliphatic alcohol or polyhydric alcohol and has 30-50% water content. Generally an essence obtained by concentrating the extracted solution is used in the astringent agent. In the case of the latter, the prune flesh is treated with an enzyme, liquiefied, the enzyme is deactivated by heating, then the liquid is filtered and preferably the remaining solid substance is removed. The obtained filtrate has a viscosity lower than that of the prune essence and yet has an excellent astringing action on skin.
Clinical Presentation

The manifestations of acute overdose include pinpoint pupils, sedation, hypotension, hypoglycemia, respiratory depression, and death.

Treatment of Overdose

In the event of overdose, the respiratory and cardiac status of the patient should be monitored carefully. When respiratory or cardiac functions are depressed, primary attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. Oxygen, IV fluids, vasopressors, and other supportive measures should be employed as indicated.

In the case of overdose, the primary management should be the re-establishment of adequate ventilation with mechanical assistance of respiration, if required. Naloxone may be of value for the management of buprenorphine overdose. Higher than normal doses and repeated administration may be necessary. The long duration of action of buprenorphine and naloxone sublingual tablets should be taken into consideration when determining the length of treatment and medical surveillance needed to reverse the effects of an overdose. Insufficient duration of monitoring may put patients at risk.
Methods and systems are provided for creating a personalized sleep classifier for a subject. Sleep data are obtained from biosignals from a subject in a High-Accuracy Sleep Study (HASS). Sleep data are also obtained from biosignals from the subject in a Simplified Sleep Study (SSS), the High-Accuracy Sleep Study being obtained simultaneously from the subject with the Simplified Sleep Study. A high-resolution HASS sleep profile is developed from the sleep data of the High-Accuracy Sleep Study. A personalized sleep classifier is created that outputs a SSS sleep profile of the subject based on the sleep data from the Simplified Sleep Study. And the personalized sleep classifier is calibrated such the SSS sleep profile output by the personalized sleep classifier based on the Simplified Sleep Study of the subject approaches or aligns with the high-resolution HASS sleep profile based on the High-Accuracy Sleep Study of the subject.
This investigator-initiated, single-site longitudinal study seeks to assess the utility of mitochondrial metabolomics -- panels of small molecules that affect mitochondrial function -- to diagnose pre-symptomatic, pre-manifest, and symptomatic Huntington's disease and serve as biomarkers for HD severity and progression. It also seeks to demonstrate that this novel biomarker in the blood has comparable value to the same analysis in spinal fluid. This research study involves 3-4 visits over 18 months. Forty volunteers with HD and 25 volunteers without HD will be included. Volunteers who have HD will have a physical examination and blood draw at each study visit. Some participants will also volunteer for optional lumbar puncture.
It is intended to provide a novel angiogenesis inhibitor which is efficacious against angiogenesis in various diseases, highly safe and highly useful in practice; and a method of screening the same. The angiogenesis inhibitor comprises, as the active ingredient, an ansamycin antibiotic such as rifampicin, rifamycin SV or 3-formyl rifamycin having been widely employed as an antibacterial agent in treating tuberculosis or infections with gram-positive bacteria. Such an active ingredient has an excellent effect of inhibiting angiogenesis. The angiogenesis inhibitor is efficacious in inhibiting angiogenesis in malignant tumor, diabetic retinopathy, retinal angiogenesis and inflammatory diseases, inhibiting angiogenesis accompanying cardiovascular remodeling, etc. and, therefore, is usable as a remedy for each of the above diseases, etc. The screening method as described above makes it possible to effectively screen an angiogenesis inhibitor by detecting an angiogenesis inhibitory signal on the bases of gene expression. ® KIPO & WIPO 2007
During routine dermatologic examination, a 77-year-old male was noted to have a firm blue subcutaneous nodule on his right lateral upper back. His past medical history included metastatic melanoma of unknown primary involving right and left axillary lymph nodes, treated with ipilimumab/nivolumab with complete response, and subsequent primary uveal melanoma. The subcutaneous nodule was located near his previous right axillary scar for metastatic melanoma. Excision of the nodule showed a plexiform neoplasm involving mid and deep dermis composed of spindle and epithelioid atypical cells admixed with numerous melanophages. Central necrosis was present. Immunohistochemical studies revealed the tumor cells to be diffusely positive for HMB45, with retained expression of BAP1 and p16. The tumor cells were negative for PRAME, nuclear expression of β-catenin, LEF1, and BRAF V600E. Molecular studies demonstrated BAP1 and GNA11 somatic mutations, a profile different from that exhibited by his prior melanoma. Collectively, these data were interpreted as a metastasis from uveal melanoma and not a recurrence of his metastatic likely cutaneous melanoma after complete response to immunotherapy. This case emphasizes the importance of molecular studies for definitive diagnosis in challenging clinical situations, especially when there is discordance among histopathological, immunohistochemical, and molecular studies. Integration of clinical, histopathological, and molecular features is warranted.
Ophthalmic compositions are provided that comprise or consist essentially of (a) ketotifen or a ketotifen salt, (b) a non-ionic tonicity agent, and (c) water. The concentration of ketotifen or the ketotifen salt is preferably from 0.01 % to 0.05 %. The non-ionic tonicity agent is preferably glycerol and the concentration of the glycerol is preferably from 4 % to 7 %. The compositions preferably have an osmolality of from 400 to 875 milliosmoles/Kg. The compositions may also contain an anti-redness agent. Methods of treating allergic conjunctivitis using the ophthalmic compositions and methods of treating dry eye disease using the ophthalmic compositions are also provided.
BACKGROUND: In vitro haemolysis is a major operational challenge for medical laboratories. A new experimental design was used to investigate under what conditions algorithms could be designed to report either quantitative or qualitative aspartate aminotransferase and lactate dehydrogenase results outside the manufacturer's haemolysis specifications. Quantitative corrections were required to meet prespecified quality specifications.
METHODS: Twenty-five patient samples were used to design reporting algorithms and another 41 patient samples were used to validate the algorithms. Aspartate aminotransferase, lactate dehydrogenase and haemolysis index were determined using a Cobas 6000 analyser (Roche diagnostics, Mannheim, Germany). Correction factors were determined, and the accuracy of the correction was investigated. Reporting algorithms were designed based on (i) the manufacturer's cut-off for the haemolysis index, (ii) corrections within the total allowable error specification and (iii) qualitative reporting based on obtained results. The impact of the reporting algorithms was retrospectively determined by recalculating six months of aspartate aminotransferase and lactate dehydrogenase results.
RESULTS: No correction for aspartate aminotransferase/lactate dehydrogenase was possible for results below the upper reference interval limit, while results equal to or greater than the upper reference interval limit could, up to mild haemolysis, be corrected within the total error criterion. All samples generated from the validated patient cohort fulfilled the set criteria. The algorithms allowed reporting 88.5% and 85.9% of otherwise unreported aspartate aminotransferase and lactate dehydrogenase results, respectively.
CONCLUSIONS: An approach is presented that allows to generate and validate reporting algorithms for aspartate aminotransferase and lactate dehydrogenase compatible with prespecified quality specifications. The designed algorithms resulted in a significant reduction of otherwise unreported aspartate aminotransferase and lactate dehydrogenase results.
Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome associated with increased myocardial stiffness and cardiac filling abnormalities. Prior studies implicated increased α-tubulin detyrosination, which is catalyzed by the vasohibin enzymes, as a contributor to increased stabilization of the cardiomyocyte microtubule network (MTN) and stiffness in failing human hearts. We explored whether increased MTN detyrosination contributed to impaired diastolic function in the ZSF1 obese rat model of HFpEF and designed a small-molecule vasohibin inhibitor to ablate MTN detyrosination in vivo. Compared with ZSF1 lean and Wistar Kyoto rats, obese rats exhibited increased tubulin detyrosination concomitant with diastolic dysfunction, left atrial enlargement, and cardiac hypertrophy with a preserved left ventricle ejection fraction, consistent with an HFpEF phenotype. Ex vivo myocardial phenotyping assessed cardiomyocyte mechanics and contractility. Vasohibin inhibitor treatment of isolated cardiomyocytes from obese rats resulted in reduced stiffness and faster relaxation. Acute in vivo treatment with vasohibin inhibitor improved diastolic relaxation in ZSF1 obese rats compared with ZSF1 lean and Wistar Kyoto rats. Vasohibin inhibition also improved relaxation in isolated human cardiomyocytes from both failing and nonfailing hearts. Our data suggest the therapeutic potential for vasohibin inhibition to reduce myocardial stiffness and improve relaxation in HFpEF.
Objective: To implement use of obstetric (OB) hospitalist telemedicine services (TeleOB) to support clinicians facing OB emergencies in low-resource hospital settings. Methods: TeleOB was staffed by OB hospitalists working at a tertiary maternity center. The service was available via real-time high-definition audio/video technology for providers at 17 outlying hospitals across a health system spanning two states. The initial 25 service activations are described. Results: TeleOB supported 17 deliveries, two postpartum emergency department (ED) consultations, and four antenatal ED consultations. In 10 of 17 (59%) deliveries, teleneonatology was jointly activated to support neonatal resuscitation. Sixteen (94%) deliveries occurred in multiparas, and five (29%) resulted from spontaneous preterm labor. Eighty percent (20/25) of activations occurred in facilities without maternity services. Conclusions: A TeleOB service staffed by OB hospitalists successfully supports hospitals in an integrated health care system. TeleOB is feasible for support of hospitals with no delivery facilities or with limited maternity care resources.
The efficacy of MENOPUR was established in one randomized, open-label, multicenter, multinational (in Europe and Israel), comparative clinical trial of women undergoing in vitro fertilization (IVF) or IVF plus intracytoplasmic injection (ICSI) to achieve pregnancy.

All women began ovarian stimulation as part of an IVF cycle following pituitary suppression with a GnRH agonist. A total of 373 patients were randomized to the MENOPUR arm. Randomization was stratified by insemination technique [conventional IVF vs. ICSI]. Efficacy was assessed based on the primary efficacy parameter of continuing pregnancy. The initial daily dose of MENOPUR was 225 International Units administered subcutaneously for five days. Thereafter, the dose was individualized according to each patient's response, up to a maximum of 450 IU/day for a total maximum duration of stimulation of 20 days. Treatment outcomes are summarized in Table 3.